all press releases

  • 02/04/20
    IRVING, Texas--(BUSINESS WIRE)--Vizient, Inc. announced today it will participate in the First Illinois chapter of Healthcare Financial Management Association & Chicago Health Executive Forum’s Managed Care Symposium. The event will be held at University Club in Chicago Feb. 6 with topics focused on improving performance through value-based transformation, Illinois Medicaid Updates and other topics that could impact providers and patients. David Levine, M.D., group senior vice presidentmore...
  • 02/03/20
    IRVING, Texas--(BUSINESS WIRE)--Vizient, Inc. announced today it has been awarded a food services contract from TPC, a Plano, Texas-based network of health care providers. With its national presence and focus on standardization, the Vizient Food Program is expected to save participating TPC members approximately 10% each year in food costs. “We’re excited to work with TPC and its members to help them realize cost savings and greater efficiencies in their food service offerings for theirmore...
  • 01/30/20
    IRVING, Texas--(BUSINESS WIRE)--Vizient, Inc. will join supply chain professionals, pharmaceutical industry representatives and other thought leaders for the Healthcare Supply Chain Association National Pharmacy Forum 2020. The conference entitled, “A 2020 Perspective on Healthcare and Pharmacy Leadership,” will be held Feb. 3-5 in Scottsdale, Arizona. Vizient experts will share their knowledge in two sessions and moderate one on Feb. 4: 503B Compounding Update 11 a.m. to noon The 503Bmore...
  • 01/29/20
    IRVING, Texas--(BUSINESS WIRE)--Vizient, Inc. released its Winter 2020 Drug Price Forecast projecting that health systems, including inpatient and non-acute environments, can expect a 3.59% increase for pharmaceutical purchases made from July 1 to June 30, 2021. While the forecasted percentage is lower than previous projections, the influence of expensive biologic therapies, oncology and oncology-related drugs, disease-modifying antirheumatic drugs (DMARDs), and immunomodulators on overallmore...
  • 01/28/20
    IRVING, Texas--(BUSINESS WIRE)--Vizient, Inc. yesterday submitted comments to the Food and Drug Administration (FDA) in response to its draft guidance, “Clinical Immunogenicity Considerations for Biosimilar and Interchangeable Insulin Products.” We applaud the FDA’s draft guidance which clarifies that a comparative clinical immunogenicity study may not be necessary for approval of certain proposed biosimilar and interchangeable insulin products. Vizient believes FDA’s draft guidance willmore...
  • 01/27/20
    IRVING, Texas--(BUSINESS WIRE)--Vizient, Inc. has identified 200 essential medications whose absence may threaten hospitals’ ability to provide immediate and high quality patient care, including 77 acute and chronic life-saving drugs that have no alternatives in the event of a supply disruption. The medications designated as essential with no alternatives include vital chemotherapy drugs and life-saving reversal agents such as epinephrine (allergic reactions) and naloxone (opioid overdoses).more...